TABLE 1

IC50 values for MAPK inhibitors in canine and human cell lines

Cell LineVemurafenibaPLX7904aSelumetinibaTrametiniba
μMμMnMnM
Canine
 Angus119 (7.6–48)21 (6.6–69)150 (41–530)6.2 (1.9–20)
 Kinsey20 (9.3–45)6.1 (5.8–6.3)18 (13–23)0.10 (0.019–0.56)
 Bliley9.0 (2.8–29)0.96 (0.43–2.1)240 (140–410)1.4 (0.39–5.6)
 Tyler126 (14–49)0.52 (0.18–1.5)140 (47–390)2.2 (0.55–9.0)
 Tyler219 (8.4–42)0.20 (0.072–0.58)390 (100–1500)3.1 (0.94–10)
Human
 A3750.35 (0.23–0.54)0.11 (0.058–0.23)81 (55–120)1.2 (0.72–2.0)
 Colo2050.077 (0.020–0.30)0.10 (0.020–0.54)100 (29–360)0.26 (0.076–0.87)
 HT290.60 (0.25–1.4)0.32 (0.075–1.3)130 (62–270)0.70 (0.17–2.9)
 RKO14 (9.5–21)2.8 (1.1–7.1)1700 (660–4600)8.6 (0.96–78)
  • a Values shown are the mean and 95% confidence interval of IC50 values determined from three to five independent experiments. Each experiment included three technical replicates for each drug concentration. The IC50 values were rounded to two significant figures.